HoFH, the International Clinical Collaborators Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Pennsylvania

About this trial

Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.

Eligibility criteria

Qualifiers

Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined

Disqualifiers

No diagnosis of HoFH

Trial design

Treatments tested in this trial

  • Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Pennsylvania

Lead sponsor

University of Amsterdam

Collaborator

University of Cape Town

Collaborator

University of Witwatersrand, South Africa

Collaborator